Tasly Group focuses on core pharma, announces asset realignment

Tasly Pharmaceutical Group (SSE:600535) is streamlining operations with a series of key moves detailed in its 2024 annual report and subsequent announcements. A key part of this realignment involves parent Tasly Group injecting CNY 4.67 billion into subsidiary Nuoyan Diagnostics to further diagnostics research and development while transferring its equity, along with all other assets, back to the original parent. The asset transfers, along with existing operational strategy, will refocus Tasly on production and pharmaceutical innovation.